keyword
MENU ▼
Read by QxMD icon Read
search

Bone scans in prostate cancer

keyword
https://www.readbyqxmd.com/read/28417160/diagnosis-of-recurrent-prostate-cancer-with-pet-ct-imaging-using-the-gastrin-releasing-peptide-receptor-antagonist-68-ga-rm2-preliminary-results-in-patients-with-negative-or-inconclusive-18-f-fluoroethylcholine-pet-ct
#1
Gesche Wieser, Ilinca Popp, H Christian Rischke, Vanessa Drendel, Anca-Ligia Grosu, Mark Bartholomä, Wolfgang A Weber, Rosalba Mansi, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer, Cordula Annette Jilg
PURPOSE/BACKGROUND: [(18)F]fluoroethylcholine ((18)FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the (68)Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive (18)FECH-PET/CT...
April 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28390646/first-line-management-of-metastatic-castrate-resistant-prostate-cancer-patients-audit-of-real-life-practices
#2
Anthony Turpin, David Pasquier, Christophe Massard, Jean-François Berdah, Stéphane Culine, Nicolas Penel
BACKGROUND: No reliable guidelines are available for choosing the best option between docetaxel and new hormonal therapies (NHTs) (i.e., abiraterone and enzalutamide) in first-line therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. We performed an audit of real-life practices. METHODS: We built an online questionnaire and distributed it with the help of French oncology networks. This questionnaire was sent to 481 physicians who treat patients with mCRPC...
April 5, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28379896/spectrum-of-metastatic-and-nonmetastatic-skeletal-findings-with-dual-phase-18f-fech-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer
#3
Athar Haroon, Rizwan Syed, Raymond Endozo, Rayjanah Allie, Alex Freeman, Mark Emberton, Jamshed Bomanji
INTRODUCTION: The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase fluorine-18-fluoroethylcholine (F-FECH) PET/CT performed during the work-up of patients referred for suspected prostate cancer relapse. MATERIALS AND METHODS: Three hundred F-FECH PET/CT scans were evaluated prospectively. The low-dose CT features of all cases were categorized as isodense, sclerotic, lytic or mixed lytic/sclerotic and maximum standardized uptake value (SUVmax) values were calculated...
May 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28317247/establishing-the-pathways-and-indications-for-performing-isotope-bone-scans-in-newly-diagnosed-intermediate-risk-localised-prostate-cancer-results-from-a-large-contemporaneous-cohort
#4
Gokul Vignesh KandaSwamy, Adam Bennett, Krishna Narahari, Owen Hughes, John Rees, Howard Kynaston
OBJECTIVE: To establish the pattern of isotope bone scan (BS) positivity in a large contemporaneous cohort of newly diagnosed localised prostate cancer (PCa) patients and compare with the European Association of Urology (EAU) guidelines. BACKGROUND: Imaging guidelines and clinical practice of using BS to stage newly diagnosed patients with intermediate risk (IR) localised PCa are not uniform in the literature. PATIENTS AND METHODS: All newly diagnosed PCa patients were discussed in a specialist multidisciplinary team (sMDT) meeting and were prospectively entered in a database...
March 20, 2017: BJU International
https://www.readbyqxmd.com/read/28296775/giant-hepatic-metastasis-in-a-patient-with-coin-like-small-cell-lung-carcinoma-incidentally-diagnosed-at-autopsy-a-case-report
#5
Decebal Fodor, Simona Gurzu, Anca Otilia Contac, Ioan Jung
RATIONALE: Encephalopathy is a rare complication of hepatic metastases. In this paper we present a case of a patient with lung cancer and metastatic-related giant hepatomegaly. PATIENT CONCERNS: A 78-year-old previously healthy male was admitted in the Emergency room in hepatic coma. DIAGNOSES: The abdominal CT scan examination revealed a huge liver filled with solid nodules. INTERVENTIONS: No interventions were performed...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28289967/a-pilot-trial-evaluating-zoledronic-acid-induced-changes-in-18-f-fmau-positron-emission-tomography-imaging-of-bone-metastases-in-prostate-cancer
#6
Ulka N Vaishampayan, Omid S Tehrani, Jawana M Lawhorn-Crews, Lance K Heilbrun, Kimberlee Dobson, Daryn Smith, Brenda Dickow, Anthony F Shields
PURPOSE: We conducted a pilot trial utilizing [(18)F]FMAU [1-(2'-deoxy-2'-[(18)F]fluoro-β-D-arabinofuranosyl thymine] as a tumor tracer in positron emission tomography (PET) and evaluated its reproducibility, and changes in maximum and peak standardized uptake value (SUVmax and SUVpeak) with zoledronic acid treatment in castrate resistant prostate cancer (CRPC) patients with bone metastases (BM). PROCEDURES: Eligible patients had CRPC with radiographic evidence of BM and creatinine clearance >30 ml/min...
March 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28285790/diagnosis-and-treatment-for-clinically-localized-prostate-cancer-adherence-to-the-european-association-of-urology-clinical-guidelines-in-a-nationwide-population-based-study-gescap-group
#7
F Gómez-Veiga, A Rodríguez-Antolín, B Miñana, C Hernández, J F Suárez, J M Fernández-Gómez, M Unda, J Burgos, A Alcaraz, P Rodríguez, R Medina, J Castiñeiras, C Moreno, E Pedrosa, J M Cózar
OBJECTIVE: To assess the adherence to European Association of Urology (EAU) guidelines in the management of prostate cancer (PCa) in Spain. PATIENTS AND METHODS: Epidemiological, population-based, study including a national representative sample of 3,918 incident patients with histopathological confirmation during 2010; 95% of the patient's sample was followed up for at least one year. Diagnosis along with treatment related variables (for localized PCa -low, intermediate, high and locally-advanced by D'Amico risk stratification) was recorded...
March 9, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28278446/fluorocholine-pet-ct-predicts-skeletal-progression-skeletal-event-and-cancer-specific-survival-in-patients-with-biochemical-relapse-for-prostate-cancer
#8
Fabio Zattoni, Emanuela Agostini, Francesco Cattaneo, Marco Maruzzo, Umberto Basso, Filiberto Zattoni, Laura Evangelista
PURPOSE: The aim of our study is to evaluate the prognostic impact of (18)F-Choline (FCh) positron emission tomography (PET)/computed tomography (CT), CT alone and methylene diphophonate bone scan (MDP-BS) in prostate cancer (PCa) patients with biochemical relapse. METHODS: We retrospectively selected 58 patients who underwent, between June 2010 and February 2013, both FCh-PET/CT and MDP-BS within a maximum time interval of 5months. All patients had a biochemical PCa recurrence after radical prostatectomy and/or radiation therapy...
February 24, 2017: Clinical Imaging
https://www.readbyqxmd.com/read/28267456/clinical-experience-with-18-f-labeled-small-molecule-inhibitors-of-prostate-specific-membrane-antigen
#9
REVIEW
Steven P Rowe, Michael A Gorin, Roberto A Salas Fragomeni, Alexander Drzezga, Martin G Pomper
Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28265811/expert-system-for-bone-scan-interpretation-improves-progression-assessment-in-bone-metastatic-prostate-cancer
#10
Fabian Haupt, Georg Berding, Ali Namazian, Florian Wilke, Alena Böker, Axel Merseburger, Lilli Geworski, Markus Antonius Kuczyk, Frank Michael Bengel, Inga Peters
INTRODUCTION: The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone(BSI) seems to represent technical progress for the quantitative assessment of bone involvement. But it is not yet clear if the automated BSI (aBSI) could contribute to improved evaluation of progression in patients under antiandrogens or chemotherapy in contrast to the visual interpretation and/or conventional biomarkers such as the prostate-specific antigen (PSA)...
April 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28258616/focal-salvage-hifu-in-radiorecurrent-prostate-cancer
#11
A Kanthabalan, M Peters, M Van Vulpen, N McCartan, R G Hindley, A Emara, M C Moore, M Arya, M Emberton, H U Ahmed
OBJECTIVE: To assess short to medium term cancer control rates and side effects of focal salvage High Intensity Focused Ultrasound (HIFU). MATERIALS AND METHODS: A retrospective registry analysis identified 150 men who underwent focal salvage HIFU (Sonablate 500) (November 2006-August 2015). Metastatic disease was excluded using the nodal assessment on the pelvic MRI, a radioisotope bone scan and PET imaging (choline-FDG-PET or Choline PET-CT). In our current clinical practice, metastatic disease must be ruled out by both Choline PET and bone scan...
March 4, 2017: BJU International
https://www.readbyqxmd.com/read/28244493/imaging-response-during-therapy-with-radium-223-for-castration-resistant-prostate-cancer-with-bone-metastases-analysis-of-an-international-multicenter-database
#12
D Keizman, M O Fosboel, H Reichegger, A Peer, E Rosenbaum, M-C Desax, V Neiman, P M Petersen, J Mueller, R Cathomas, M Gottfried, H Dresler, D Sarid, W Mermershtain, K Rouvinov, J Mortensen, S Gillessen, G Daugaard, A Omlin
BACKGROUND: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment. METHODS: We retrospectively evaluated the computed tomography (CT) and bone scintigraphy response of metastatic castration-resistant prostate cancer (CRPC) patients treated with radium-223, in eight centers in three countries. RESULTS: A total of 130 patients were included, the majority (n=84, 65%) received radium-223 post docetaxel...
February 28, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28217018/skeletal-metastases-presenting-as-superscan-on-technetium-99m-methylene-diphosphonate-whole-body-bone-scintigraphy-in-different-type-of-cancers-a-5-year-retro-prospective-study
#13
P Ram Manohar, Tanveer A Rather, Shoukat H Khan, Dharmender Malik
The purpose of the study is to find out the overall incidence of superscan among different type of cancers, causes of superscan and its relationship with other parameters such as age, sex, duration of disease, and serum alkaline phosphatase (ALP) levels. This was a retro-prospective study. Records of all previous bone scans and reported patients of superscan were re-evaluated retrospectively. Patients who were diagnosed as having superscan in the preceding 3 years with confirmed histopathological diagnosis were included in the retrospective group...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28217016/prostate-specific-antigen-as-a-risk-factor-for-skeletal-metastasis-in-native-ethnic-african-men-with-prostate-cancer-a-case-control-study
#14
Ayman M Qureshi, Khalid Makhdomi, William Stones
Prostate cancer is the most common noncutaneous cancer in males. Men of African origin are at a significantly higher risk as reflected in the higher incidence and mortality rates in this racial group. Metastases incidence increases parallel to serum levels of prostate-specific antigen (PSA), contributing significantly to morbidity and mortality. Staging of the disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions that these scans may be omitted in some situations in patients with low prostate specific antigen levels have drawn attention to the matter...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28216327/combined-whole-body-and-multiparametric-prostate-magnetic-resonance-imaging-as-a-1-step-approach-to-the-simultaneous-assessment-of-local-recurrence-and-metastatic-disease-after-radical-prostatectomy
#15
Nicola L Robertson, Evis Sala, Matthias Benz, Jonathan Landa, Peter Scardino, Howard I Scher, Hedvig Hricak, Hebert A Vargas
PURPOSE: We report our initial experience with whole body and dedicated prostate magnetic resonance imaging as a single examination to assess local recurrence and metastatic disease in patients with suspected recurrent prostate cancer after radical prostatectomy. MATERIALS AND METHODS: In this institutional review board approved, retrospective, single center study 76 consecutive patients with clinically suspected recurrent prostate cancer following radical prostatectomy underwent combined whole body and dedicated prostate magnetic resonance imaging at a single session from October 10, 2014 to January 2016...
February 16, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28210997/3d-skeletal-uptake-of-18-f-sodium-fluoride-in-pet-ct-images-is-associated-with-overall-survival-in-patients-with-prostate-cancer
#16
Sarah Lindgren Belal, May Sadik, Reza Kaboteh, Nezar Hasani, Olof Enqvist, Linus Svärm, Fredrik Kahl, Jane Simonsen, Mads H Poulsen, Mattias Ohlsson, Poul F Høilund-Carlsen, Lars Edenbrandt, Elin Trägårdh
BACKGROUND: Sodium fluoride (NaF) positron emission tomography combined with computer tomography (PET/CT) has shown to be more sensitive than the whole-body bone scan in the detection of skeletal uptake due to metastases in prostate cancer. We aimed to calculate a 3D index for NaF PET/CT and investigate its correlation to the bone scan index (BSI) and overall survival (OS) in a group of patients with prostate cancer. METHODS: NaF PET/CT and bone scans were studied in 48 patients with prostate cancer...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28152910/choosing-wisely-in-oncology-are-we-ready-for-value-based-care
#17
Doug Blayney, Mohammad Jahanzeb, Pamela Kadlubek, August Knape, Merry Jennifer Markham, Trang Pham, Tracey L Evans
275 Background: The Choosing Wisely (CW) Campaign challenges patients, healthcare providers, and specialty disease societies to make better decisions about healthcare delivery. In 2012, Schnipper et al. published ASCO's Top Five List targeting overuse of medications, tests, and procedures that are costly and lack evidence. 1.) Do not use cancer-directed therapy for patients with low performance status (undocumented, 3 or 4). 2.) Do not use PET, CT and radionuclide bone scans in the staging of early prostate cancer...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28110835/prognostic-value-of-automated-bone-scan-index-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-enzalutamide-or-abiraterone-acetate
#18
Yasuhide Miyoshi, Koichi Uemura, Takashi Kawahara, Shuko Yoneyama, Yusuke Hattori, Jun-Ichi Teranishi, Jun-Ichi Ohta, Shigeo Takebayashi, Yumiko Yokomizo, Narihiko Hayashi, Masahiro Yao, Hiroji Uemura
PURPOSE: Bone scan index (BSI) is an objective tool for quantifying bone metastasis load. We assessed its prognostic usefulness in patients with metastatic castration-resistant prostate cancer (CRPC) treated with enzalutamide (ENZ) or abiraterone acetate (AA). MATERIALS AND METHODS: We analyzed 40 patients who received ENZ or AA treatment (ENZ/AA) for metastatic CRPC. The Cox proportional hazards model and a C-index were used to investigate associations between overall survival (OS) and BSI, and patient age, prostate-specific antigen, time to CRPC, previous docetaxel use, and pain...
December 29, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28103659/-a-case-of-giant-prostate-carcinoma-effectively-treated-with-external-beam-radiation-therapy
#19
Sohei Kanda, Shintaro Narita, Naoki Komine, Seiichi Kitajima, Misa Yamauchi, Akihiro Sugita, Yutaka Saito, Tomonori Habuchi
We present a case of gigantic prostate tumor in a patient with castration-resistant prostate cancer with successful local control by external-beam radiation therapy. A 71-year-old man was shown to have a prostate specific antigen (PSA)level of 24.5 ng/ml, Gleason 9, cT2N1M1a, prostate adenocarcinoma with an estimated prostate volume of 26.9 g. He achieved a PSA nadir at 4 months after the initial androgen deprivation therapy and was diagnosed with castration-resistant prostate cancer three years later. Eight months after the diagnosis of castration-resistant prostate cancer, he visited our hospital due to urinary retention...
December 2016: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28103574/68ga-psma-11-pet-ct-for-prostate-cancer-staging-and-risk-stratification-in-chinese-patients
#20
Shiming Zang, Guoqiang Shao, Can Cui, Tian-Nv Li, Yue Huang, Xiaochen Yao, Qiu Fan, Zejun Chen, Jin Du, Ruipeng Jia, Hongbin Sun, Zichun Hua, Jun Tang, Feng Wang
We evaluated the clinical utility of 68Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment-naïve PCa, 15 mCRPC]) showed PSMA-avid lesions on 68Ga-PSMA-11 images...
February 14, 2017: Oncotarget
keyword
keyword
63986
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"